Imperial College London
Portrait Picture

Peter Openshaw - Professor of Experimental Medicine

Faculty of Medicine, National Heart & Lung Institute

Proconsul, Professor of Experimental Medicine
 
 
 
//

Contact

 

+44 (0)20 7594 3854p.openshaw Website CV

 
 
//

Assistant

 

Ms Gale Lewis +44 (0)20 7594 0944

 
//

Location

 

353Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Chang:2022:10.1177/01945998211064275,
author = {Chang, CWD and McCoul, ED and Briggs, SE and Guardiani, EA and Durand, ML and Hadlock, TA and Hillel, AT and Kattar, N and Openshaw, PJM and Osazuwa-Peters, N and Poetker, DM and Shin, JJ and Chandrasekhar, SS and Bradford, CR and Brenner, MJ},
doi = {10.1177/01945998211064275},
journal = {Otolaryngology - Head and Neck Surgery},
pages = {803--820},
title = {Corticosteroid use in otolaryngology: current considerations during the COVID-19 era},
url = {http://dx.doi.org/10.1177/01945998211064275},
volume = {167},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Objective:To offer pragmatic, evidence-informed advice on administering corticosteroids in otolaryngology during the coronavirus disease 2019 (COVID-19) pandemic, considering therapeutic efficacy, potential adverse effects, susceptibility to COVID-19, and potential effects on efficacy of vaccination against SARS-CoV-2, which causes COVID-19.Data Sources:PubMed, Cochrane Library, EMBASE, CINAHL, and guideline databases.Review Methods:Guideline search strategies, supplemented by database searches on sudden sensorineural hearing loss (SSNHL), idiopathic facial nerve paralysis (Bell’s palsy), sinonasal polyposis, laryngotracheal disorders, head and neck oncology, and pediatric otolaryngology, prioritizing systematic reviews, randomized controlled trials, and COVID-19–specific findings.Conclusions:Systemic corticosteroids (SCSs) reduce long-term morbidity in individuals with SSNHL and Bell’s palsy, reduce acute laryngotracheal edema, and have benefit in perioperative management for some procedures. Topical or locally injected corticosteroids are preferable for most other otolaryngologic indications. SCSs have not shown long-term benefit for sinonasal disorders. SCSs are not a contraindication to vaccination with COVID-19 vaccines approved by the US Food and Drug Administration. The Centers for Disease Control and Prevention noted that these vaccines are safe for immunocompromised patients.Implications for Practice:SCS use for SSNHL, Bell’s palsy, laryngotracheal edema, and perioperative care should follow prepandemic standards. Local or topical corticosteroids are preferable for most other otolaryngologic indications. Whether SCSs attenuate response to vaccination against COVID-19 or increase susceptibility to SARS-CoV-2 infection is unknown. Immunosuppression may lower vaccine efficacy, so immunocompromised patients should adhere to recommended infection control practices. COVID-19 vaccination with Pfizer-BioNTech, Moderna, or Johnson & Johns
AU  - Chang,CWD
AU  - McCoul,ED
AU  - Briggs,SE
AU  - Guardiani,EA
AU  - Durand,ML
AU  - Hadlock,TA
AU  - Hillel,AT
AU  - Kattar,N
AU  - Openshaw,PJM
AU  - Osazuwa-Peters,N
AU  - Poetker,DM
AU  - Shin,JJ
AU  - Chandrasekhar,SS
AU  - Bradford,CR
AU  - Brenner,MJ
DO  - 10.1177/01945998211064275
EP  - 820
PY  - 2022///
SN  - 0194-5998
SP  - 803
TI  - Corticosteroid use in otolaryngology: current considerations during the COVID-19 era
T2  - Otolaryngology - Head and Neck Surgery
UR  - http://dx.doi.org/10.1177/01945998211064275
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000730398700001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://journals.sagepub.com/doi/10.1177/01945998211064275
UR  - http://hdl.handle.net/10044/1/93569
VL  - 167
ER  -
Download